Coherus Biosciences Inc
CHRS
Get informed when a big investor buys or sells
+ FollowMarket Cap$156.05M
Close$
$-0.25
124.3% downside
Current Fair Value
124.3% downsideOvervalued by 124.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $156.05 Million |
|---|---|
| Enterprise Value | $110.83 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.45 |
| Beta | 0.99 |
| Outstanding Shares | 154,816,912 |
Return
| Return on Equity | -772.64% |
|---|---|
| Return on Assets | -245.87% |
| Return on Invested Capital | -139.20% |
Valuation & Multiples
| P/E Ratio | -0.99 |
|---|---|
| PEG | 0.93 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.18 |
| Enterprise Value to EBIT | -0.69 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | 0.62 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$14.41 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$15.98 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 471.04% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.04%▼ 46.19% |
|---|---|
| Total Invested | $70,458▼ 99.93% |
| Investors Holding | 1▼ 151.00% |
ESG Score
No data
About Coherus Biosciences Inc
CEO: Dennis Lanfear